# US 2025/0025584 A1 · Radiopharmaceutical treatment methods and use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0025584 A1
- Document ID: US20250025584A1
- Status: Published application
- Kind: A1
- Application number: 18/675,346
- Filed: 2024-05-28
- Published: 2025-01-23
- Earliest claimed: 2021-11-29
- Assignees: POINT Biopharma Inc.
- Applicants: Point Biopharma, Inc.
- Inventors: Neil FLESHNER; Jessica JENSEN; Joe MCCANN
- Web page: https://patentgrep.com/patent/US20250025584A1

## CPC

- A61K 51/088: {conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10)}
- A61K 51/0402: {carboxylic acid carriers, fatty acids (amino acids A61K51/0406)}
- A61K 51/0497: {conjugates with a carrier being an organic compounds}
- A61P 35/00: Antineoplastic agents
- C07B 59/008: {Peptides; Proteins}
- C07F 5/003: {without C-Metal linkages}
- A61K 2121/00: Preparations for use in therapy
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

In one aspect, therapeutic use, methods of treatment and kits comprising 177Lu-PSMA I&T are provided for subjects exhibiting prostate cancer progression following administration with one or more androgen receptor inhibitor agents.

## Claims

### Claim 1

A method for treating a subject suffering from prostate cancer, wherein the subject (i) has exhibited prostate cancer progression during or after treatment with one or more androgen receptor inhibitor agents and (ii) is chemotherapy-naïve before treatment with the one or more androgen receptor inhibitor agents; said method comprising:
administering to the subject an amount of a complex of lutetium-177 and EuK-Sub-kf-iodo-y-DOTAGA providing from a 4 to 10 Gbq dose at least four times, at four week or longer intervals between doses.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The method of claim 1 wherein the subject has exhibited cancer progression during treatment with one or more of abiraterone, enzalutamide, apalutamide, darolutamide, cimetidine, orteronel, galeterone, seviteronel, topilutamide, bicalutamide, fluamide and/or nilutamide.

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The method of claim 1 wherein the subject has exhibited cancer progression following at least two months of treatment with one or more androgen receptor inhibitor agents.

### Claim 7 (depends on 1)

The method of claim 1 wherein treatment with one or more androgen receptor inhibitor agents is the only chemotherapy administered to the subject before administering the lutetium-177 labeled PSMA-targeted radioligand.

### Claim 8 (depends on 1)

The method of claim 1 wherein the subject is taxane chemotherapy-naïve and/or taxane chemotherapy adverse.

### Claim 9 (depends on 1)

The method of claim 1 wherein the subject exhibits elevated PSMA expression relative to a healthy subject.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The method of claim 1 wherein the subject exhibits PSMA expression standard uptake value (SUV)max≥15 at one site of disease and/or SUVmax>10 at all measurable disease sites.

### Claim 12 (depends on 1)

The method of claim 1 wherein the subject exhibits at least 1 positive lesion SUVmax≥10.

### Claim 13 (depends on 1)

The method of claim 1 wherein the subject exhibits elevated PSA levels.

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16 (depends on 1)

The method of claim 1 wherein administration of one or more androgen receptor inhibitor agents is terminated before administering the complex of lutetium-177 and EuK-Sub-kf-iodo-y-DOTAGA.

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19 (depends on 1)

The method of claim 1 wherein the subject is suffering from metastatic castration-resistant prostate cancer (mCRPC).

### Claim 20 (depends on 19)

The method of claim 19 wherein the subject is suffering from metastatic castration-resistant prostate cancer (mCRPC) with prostate-specific membrane antigen (PSMA)-avid lesions.

### Claim 21 (depends on 1)

The method of claim 1 wherein the complex of lutetium-177 and EuK-Sub-kf-iodo-y-DOTAGA is administered in combination with one or more distinct chemotherapeutic agents.

### Claim 22 (depends on 1)

The method of claim 1 wherein the complex of lutetium-177 and EuK-Sub-kf-iodo-y-DOTAGA comprises the following structure:

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26

A kit, comprising:
a pharmaceutical preparation of a complex of lutetium-177 and EuK-Sub-kf-iodo-y-DOTAGA suitable for intravenous administration to a subject, and in an amount sufficient to provide from a 4 to 10 Gbq dose; and
a package insert containing instructions for use of the agent in the treatment of a subject exhibiting prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who has previously been treated with androgen receptor (AR) pathway inhibition but which subject is taxane chemotherapy-naïve or taxane chemotherapy adverse.

### Claim 27

(canceled)

### Claim 28

(canceled)

### Claim 29

(canceled)

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim 32 (depends on 26)

The kit of claim 26, wherein the lutetium-177 EuK-Sub-kf-iodo-y-DOTAGA complex is provided in a single dose form sufficient to provide 6.8 GBq+/−10% within shelf-life.

### Claim 33

(canceled)

### Claim 34 (depends on 26)

The kit of claim 26, wherein the pharmaceutical preparation includes Sodium Ascorbate at a concentration of 55-75 mg/mL and Sodium Gentisate at a concentration of 16-36 mg/mL and has a pH in the range of 5.0-7.0.

### Claim 35 (depends on 26)

The kit of claim 26, wherein the pharmaceutical preparation has a radioactive concentration (RAC) of 0.5 to 1.2 GBq/mL at end of synthesis and formulation of the pharmaceutical preparation.

### Claim 36 (depends on 26)

The kit of claim 26, wherein the pharmaceutical preparation has a total peptide content of less than or equal to 250 μg (sum of EuK-Sub-kf-iodo-y-DOTAGA and lutetium-177 EuK-Sub-kf-iodo-y-DOTAGA complex).

### Claim 37 (depends on 26)

The kit of claim 26, wherein the pharmaceutical preparation is provided in a single dosage vial.

### Claim 38 (depends on 26)

The kit of claim 26, wherein the pharmaceutical preparation is provided in a disposable syringe with syringe shield for handheld infusion administration.

### Claim 39 (depends on 26)

The kit of claim 26, wherein the kit includes a radiation shielded pig in which the pharmaceutical preparation is transported in the packaged kit.

### Claim 40

(canceled)

### Claim 41

(canceled)
